Drug intelligence / Profile preview

FPE015

Development stage: Discontinued
Lead developer: Guangdong Fapon Biopharma
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

FPE015 is a trispecific antibody developed by Guangdong Fapon Biopharma. It targets three immune checkpoint proteins—CD112R (also known as PVRIG), PD-L1 (Programmed death-ligand 1), and TIGIT (T cell immunoglobulin and ITIM domains). The drug acts as an antagonist or inhibitor to these targets, aiming to enhance anti-tumor immune responses by blocking multiple inhibitory pathways that suppress T-cell activity in the tumor microenvironment. Its primary therapeutic area was neoplasms (cancer). Development of FPE015 has been discontinued at the preclinical stage[1][4].

Targets

PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)CD274 (Programmed cell death protein 1 ligand 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on FPE015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPE015.